{
    "nct_id": "NCT04467723",
    "official_title": "CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study",
    "inclusion_criteria": "* Participant or legal representative is able to provide written informed prior to performing any protocol-related procedures\n* Is willing and able to comply with scheduled visits, treatment schedule, laboratory testing and other requirements of the study\n* Men or women at least 18 years of age with histologically or cytologically confirmed non-small cell lung cancer\n* Previous history of other than lung cancer is allowed if no active treatment for that cancer within 1 year\n* Life expectancy of at least 6 months\n* De novo stage IV or recurrent NSCLC without actionable mutation (e.g. EGFR/ ALK/ ROS-1) that was previously treated with either PD-1 / PD-L1 or the combination of PD1/PDL1 and cytotoxic chemotherapy, no more than 2 systemic regimens for metastatic disease with measurable disease *. Maintenance therapy will be considered part of the 1 regimen\n* At least 1 measurable lesion\n* PDL1 TPS score less than 1% or unknown: first-line must be PD1/PDL1 inhibitor in combination with chemotherapy\n* Early stage (I-III) NSCLC treated with adjuvant or neoadjuvant chemotherapy then PD1/PDL1 inhibitor treatment for recurrent disease\n* Recurrent Unresectable stage III NSCLC treated with prior chemoradiation followed by maintenance PD1/PDL1 inhibitor with measurable disease\n* Eastern Cooperative Group (ECOG) Performance Status 0 - 2\n* Is able to swallow oral medications\n* Adequate hematologic function\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* The presence of any other concurrent severe and/or uncontrolled medical condition that would, in the investigator or treating physician's judgement, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol\n* Has received investigational agents within 14 days or 5 half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment\n* Has a known hypersensitivity to atezolizumab or pirfenidone\n* Has active medical or psychiatric illness that would interfere with the study treatment\n* Has uncontrolled diabetes\n* Has any of the following cardiac diagnoses:\n\nUnstable angina Myocardial infarction within 6 months Uncontrolled congestive heart failure Left ventricular ejection fraction < 35%\n\n* Has a history of any Grade 3 or 4 toxicities to a prior checkpoint inhibitor treatment\n* Is pregnant or breast feeding\n* Uncontrolled HIV\n* Clinically diagnosed with grade 2 or 3 radiation-induced lung injury within the last 3 months prior to registering for the study\n* Has a history of idiopathic pneumonitis that required systemic agent including steroid\n* Has drug-induced pneumonitis\n* Has evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Smoker of more than 1 pack / day\n* Has active peptic ulcer diagnosed within 4 weeks of enrollment\n* Active infection requiring systemic treatment\n* Current use of systemic antibacterial or antifungal agent\n* Prior monoclonal antibody within 4 weeks before study Day 1 Exception: The use of denosumab\n* Patient not recovered to â‰¤ Grade 1 from AEs due to agents administered more than 4 weeks earlier\n* Concurrent use of other investigational agents\n* Uncontrolled or symptomatic brain metastasis or leptomeningeal disease that requires use of steroids\n* Use of strong CYP1A2 inhibitors\n* Previous history of cancer with active treatment within less than 1 year of enrollment\n* Active auto-immune diseases",
    "miscellaneous_criteria": ""
}